|
Dec 5
|
1 Promising Stock Down 66% That Could Skyrocket in 2024
|
|
Nov 29
|
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
|
|
Nov 27
|
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 69%
|
|
Aug 30
|
Editas Medicine Announces Upcoming Investor Events
|
|
Aug 28
|
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
|
|
Jun 29
|
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
|
|
Jun 28
|
Is Editas Medicine Stock a Buy Now?
|
|
May 1
|
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
|
|
Apr 27
|
Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Apr 27
|
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
|
|
Apr 26
|
12 Gene Editing Stocks With the Best Long-Term Potential
|
|
Apr 26
|
Earnings Preview: Editas Medicine (EDIT) Q1 Earnings Expected to Decline
|